共 8 条
- [1] Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL[J]. BLOOD, 2016, 127 (20) : 2411 - 2415Barr, Paul M.Saylors, Gene B.Spurgeon, Stephen E.Cheson, Bruce D.Greenwald, Daniel R.O'Brien, Susan M.Liem, Andre K. D.Mclntyre, Rosemary E.Joshi, AdarshAbella-Dominicis, EstebanHawkins, Michael J.Reddy, AnitaDi Paolo, JulieLee, HankHe, JoyceHu, JingDreiling, Lyndah K.Friedberg, Jonathan W.
- [2] Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma[J]. BLOOD, 2015, 125 (21) : 3357 - 3359Cheah, Chan YoonNastoupil, Loretta J.Neelapu, Sattva S.Forbes, Sheryl G.Oki, YasuhiroFowler, Nathan H.
- [3] Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial[J]. LANCET ONCOLOGY, 2014, 15 (12) : 1311 - 1318Fowler, Nathan H.Davis, R. EricRawal, SeemaNastoupil, LorettaHagemeister, Fredrick B.McLaughlin, PeterKwak, Larry W.Romaguera, Jorge E.Fanale, Michelle A.Fayad, Luis E.Westin, Jason R.Shah, JatinOrlowski, Robert Z.Wang, MichaelTurturro, FrancescoOki, YasuhiroClaret, Linda C.Feng, LeiBaladandayuthapani, VeerabhadranMuzzafar, TariqTsai, Kenneth Y.Samaniego, FelipeNeelapu, Sattva S.
- [4] Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (04) : 511 - 518Herrmann, AnninaHoster, EvaZwingers, ThomasBrittinger, GuenterEngelhard, MarianneMeusers, PeterReiser, MarcelForstpointner, RoswithaMetzner, BerndPeter, NormaWoermann, BernhardTruemper, LorenzPfreundschuh, MichaelEinsele, HermannHiddemann, WolfgangUnterhalt, MichaelDreyling, Martin
- [5] Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (19) : 1835 - 1844Ruan, JiaMartin, PeterShah, BijalSchuster, Stephen J.Smith, Sonali M.Furman, Richard R.Christos, PaulRodriguez, AmelynSvoboda, JakubLewis, JessicaKatz, OrelColeman, MortonLeonard, John P.
- [6] Smith SM, 2017, LANCET HAEMATOL
- [7] Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience[J]. BLOOD, 2013, 122 (06) : 981 - 987Tan, DarylHorning, Sandra J.Hoppe, Richard T.Levy, RonaldRosenberg, Saul A.Sigal, Bronislava M.Warnke, Roger A.Natkunam, YasodhaHan, Summer S.Yuen, AlanPlevritis, Sylvia K.Advani, Ranjana H.
- [8] Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103[J]. BLOOD, 2016, 128 (21) : 2510 - 2516Ujjani, Chaitra S.Jung, Sin-HoPitcher, BrandelynMartin, PeterPark, Steven I.Blum, Kristie A.Smith, Sonali M.Czuczman, MyronDavids, Matthew S.Levine, EllisLewis, Lionel D.Smith, Scott E.Bartlett, Nancy L.Leonard, John P.Cheson, Bruce D.